Twist Bioscience Corp
$ 109.08
-5.16%
06 Aug - close price
- Market Cap 6,840,126,000 USD
- Current Price $ 109.08
- High / Low $ 113.76 / 108.62
- Stock P/E N/A
- Book Value 7.32
- EPS -2.12
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.13 %
- ROE -0.30 %
- 52 Week High 115.56
- 52 Week Low 23.30
About
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company is headquartered in South San Francisco, California.
Analyst Target Price
$100.89
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-03 | 2026-05-04 | 2026-02-02 | 2025-11-14 | 2025-08-04 | 2025-05-05 | 2025-02-03 | 2024-11-18 | 2024-08-02 | 2024-05-02 | 2024-02-02 | 2023-11-17 |
| Reported EPS | -0.56 | -0.6 | -0.5 | -0.45 | -0.47 | -0.66 | -0.53 | -0.59 | -0.7 | -0.79 | -0.75 | -0.75 |
| Estimated EPS | -0.5 | -0.53 | -0.52 | -0.5 | -0.57 | -0.56 | -0.63 | -0.69 | -0.77 | -0.81 | -0.77 | -0.86 |
| Surprise | -0.06 | -0.07 | 0.02 | 0.05 | 0.1 | -0.1 | 0.1 | 0.1 | 0.07 | 0.02 | 0.02 | 0.11 |
| Surprise Percentage | -12% | -13.2075% | 3.8462% | 10% | 17.5439% | -17.8571% | 15.873% | 14.4928% | 9.0909% | 2.4691% | 2.5974% | 12.7907% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TWST
2026-08-07 23:39:45
Twist Bioscience Corporation (NASDAQ: TWST) released its Q3 2026 earnings call presentation. The company reported an EPS of -$0.56, missing estimates by $0.38, while revenue reached $118.38M, surpassing expectations by $3.83M and representing a 23.24% year-over-year increase. This presentation was published in conjunction with their earnings call.
2026-08-06 21:39:46
Twist Bioscience Corporation (NASDAQ:TWST) has received a "Moderate Buy" consensus recommendation from brokerages, with eight buy ratings, one hold, and one sell among ten analysts. Despite an average 12-month price target of $98.30, below its recent opening price of $115.01, the company reported strong quarterly revenue of $118.38 million, up 23.2% year-over-year. However, it missed EPS estimates with an adjusted loss of $0.56 per share, and insiders have sold approximately $4.2 million worth of stock in the last quarter.
2026-08-06 15:10:04
FMR LLC has filed a Schedule 13G, disclosing a beneficial ownership of 7.6% in Twist Bioscience Corp (TWST) as of June 30, 2026. This translates to 4,703,044.11 shares, with FMR LLC holding sole dispositive power over all these shares and sole voting power over 4,701,268.00 shares. Abigail P. Johnson is also listed as a reporting person with sole dispositive power over the same number of shares.
2026-08-06 12:10:04
Following Twist Bioscience Corporation's latest third-quarter results, analysts have updated their forecasts, lifting the consensus price target to US$104, a 13% increase. This comes despite the company still being loss-making, driven by an improved revenue outlook of US$539.2m for 2027. While revenue growth is expected to align with the wider industry, the upgraded price target suggests analysts see improved intrinsic value over time.
2026-08-05 21:32:59
Twist Bioscience has successfully completed an underwritten stock offering, selling 3,125,000 shares of common stock at $96.00 per share, with the underwriters fully exercising their option for an additional 468,750 shares. This offering is expected to generate approximately $327.1 million in net proceeds after accounting for discounts and expenses. The transaction, led by major financial institutions, is anticipated to finalize around August 6, 2026, and aims to raise capital and enhance the company's liquidity.
2026-08-05 20:47:00
Twist Bioscience (TWST) saw its stock jump over 16% after reporting strong Q3 revenue, exceeding consensus, and raising its Q4 and FY26 revenue guidance. The company also announced an upsized $300M stock offering to fund R&D and manufacturing expansion, which, despite dilution, is seen as bolstering its balance sheet for future growth in synthetic DNA and AI drug discovery. Analysts like TD Cowen and Baird have raised price targets to $115, maintaining bullish ratings due to the positive outlook and strategic investments.
